Axcan, Il Yang Pharma Co. Ltd. deal

AXP received an option to exclusively license Il Yang's IY-81149 antiulcerant proton-pump inhibitor, which is in Phase II testing, outside China and Korea. Il Yang, in turn, received an option to excl...